AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

U.S. stock indexes were drifting higher in early trading Tuesday as Wall Street closes out another milestone-shattering year ...

U.S. equities slumped at midday after the December jobs report came in higher than anticipated, putting more Federal Reserve rate cuts in doubt.

INR:7252. picvook tv Pfizer and Eli Lilly are ahead of AbbVie and are closely following the new battlefield of JAK inhibitors. Is this the place? New tumor immunothera ...

Robert F. Kennedy Jr. stated desire to ban drug commercials from TV seems unlikely to become reality, according to ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

If you want to know who really controls AbbVie Inc. (NYSE:ABBV), then you'll have to look at the makeup of its share registry. With 73% stake, institutions possess the maximum shares in the company.

Jan 6 (Reuters) - AbbVie (ABBV.N), opens new tab lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other long-term stocks. To select stocks with long-term growth potential, investors should focus on ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...